ClinicalTrials.gg
TerminatedNCT04899232Updated Sep 7, 2022Results posted

Antithrombin III in Infectious Disease Caused by COVID-19

A Phase 2 interventional study of Antithrombin III in Antithrombin III Deficiency and Covid19, sponsored by Enrique Ginzburg. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-07.

Sponsored by Enrique Ginzburg · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
There are fewer potential patients and an early conclusion of the study would be beneficial in an attempt to finish in a reasonable time and keep the cohorts homogenous.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,860 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
802nd of 1,322
52 · median 92
Started
2021
with 503 others
Phase 2
350 of 1,860
15 open now
Registered
1,145th of 1,860
by date

Among the 1,860 studies in COVID-19 with a site in United States, this one is the 802nd largest by enrollment of the 1,322 interventional ones that give a count, is one of 504 that started in 2021, is one of 350 in phase 2, and was the 1,145th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,860 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,860 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research study is to see if participants who have SARS-CoV-2 and low levels of AT3 in the blood will benefit by being given AT3.

03

Conditions studied

  • Antithrombin III Deficiency
  • Covid19

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. >18y of age,
  2. Subject or proxy who can provide
  3. Positive SARS-COV-2 by Polymerase Chain Reaction (PCR) or as determined by clinical team

Exclusion criteria

EXCLUSION CRITERIA:

  1. Adults or Proxy unable to consent
  2. Individuals who are not yet adults (infants, children, teenagers)
  3. Pregnant women
  4. Prisoners
  5. Patients expected to die within 24 hours or with a "do not resuscitate" order,
  6. Multi-organ failure,
  7. History of or allergy to any component of the study drug,
  8. Ongoing massive surgical or unexplained bleeding,
  9. History of bleeding or clotting disorder,
  10. Severe traumatic brain injury (Glasgow Coma Scale \<6),
  11. Spinal or multiple-trauma,
  12. Cancer (incurable/terminal phase) and/or patients receiving palliative care,
  13. Enrollment in another concurrent clinical interventional study if considered interfering with this study objectives
  14. Per study team discretion, any condition(s) that may prevent safe treatment, preclude adequate evaluation or adding further risk to their underlying illness.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    AT3 less than 100% with SOC plus AT3 supplement

    Participants in this group, with endogenous Antithrombin lll less than 100%, will receive 5 doses of supplemental Antithrombin III on Days 1, 3, 5, 7 and 9, in addition to standard of care (SOC) treatment.

    Drug: Antithrombin III

  • No intervention
    AT3 less than 100% with SOC only

    Participants in this group, with endogenous Antithrombin III less than 100%, will receive SOC treatment only.

  • No intervention
    AT3 more than 100% with SOC only

    Participants in this group, with endogenous Antithrombin III more than 100%, will receive SOC treatment only.

Interventions

  • Five total doses of daily 1,821 to 9,100 IUs Antithrombin III, depending on participant's weight, will be administered intravenously every other infusion day (Days 1, 3, 5, 7 and 9).

    Also known as: Thrombate III

06

What researchers measure

Primary outcomes

  1. Change in ISTH DIC Score

    As measured by the International Society of Thrombosis and Haemostasis Disseminated Intravascular Coagulation scale (ISTH DIC) which has a total score ranging from 0-8 with a score of 5 and higher indicating overt DIC.

    Time frame: Baseline, Day 9

Secondary outcomes

  1. Change in D-Dimer Levels

    D-Dimer levels assessed from blood samples will be evaluated in mcg/ml D-Dimer Units (DDU)

    Time frame: Baseline, Day 9

  2. Change in Fibrinogen Levels

    Fibrinogen levels assessed from blood samples will be evaluated in mg/dL.

    Time frame: Baseline, Day 9

  3. Change in Prothrombin Time

    Prothrombin time assessed from blood samples will be evaluated in seconds.

    Time frame: Baseline, Day 9

  4. Length of Hospital Stay

    Length of Hospital Stay reported in days.

    Time frame: Up to 60 days

  5. Mortality Rate

    The number of participants with reported death.

    Time frame: Up to 60 days

  6. Pulmonary Function

    Pulmonary Function will be reported as the mean days the participant was on any of the following: mechanical ventilation and/or Extracorporeal Membrane Oxygenation (ECMO) use.

    Time frame: Up to 60 days

  7. Change in SOFA Scores

    Sequential Organ Failure Assessment (SOFA) is scored from 0-4 with the higher score indicating more organ failure.

    Time frame: Baseline, Day9

  8. Change in SOFA Respiratory Sub Score

    SOFA Respiratory Sub Score is scored from 0-4 with the higher score indicating worse organ failure.

    Time frame: Baseline, Day 9

  9. Number of Events of Venous Thromboembolism

    Number of events of venous thromboembolisms from admission to hospital discharge.

    Time frame: Up to 60 days

  10. Number of Events of Major Bleeding

    Number of events of major bleeding from admission to hospital discharge.

    Time frame: Up to 60 days

07

Results

Posted Sep 7, 2022
Limitations and caveats
With decreased Coronavirus disease of 2019 (COVID-19) cases, enrollment slowed leading to the early termination of the trial; the target number of 75 enrolled patients was not reached. Hesitancy to participate in the trial was noted.

Participant flow

Screening Period
Participant flow — Screening Period
MilestoneAT3 Less Than 100% With SOC Plus AT3 SupplementAT3 Less Than 100% With SOC OnlyAT3 More Than 100% With SOC Only
Started202012
Completed152012
Not completed500
Withdrew: Physician decision100
Withdrew: Withdrawal by subject100
Withdrew: Participant discharged before receiving intervention300
Treatment Period
Participant flow — Treatment Period
MilestoneAT3 Less Than 100% With SOC Plus AT3 SupplementAT3 Less Than 100% With SOC OnlyAT3 More Than 100% With SOC Only
Started152012
Completed152012
Not completed000

Outcome measures

PrimaryChange in ISTH DIC Score

As measured by the International Society of Thrombosis and Haemostasis Disseminated Intravascular Coagulation scale (ISTH DIC) which has a total score ranging from 0-8 with a score of 5 and higher indicating overt DIC.

Time frame:
Baseline, Day 9
Reported as:
Mean · score on a scale
Change in ISTH DIC Score
score on a scaleAT3 Less Than 100% With SOC Plus AT3 SupplementAT3 Less Than 100% With SOC OnlyAT3 More Than 100% With SOC Only
Change in ISTH DIC Score0.27 ± 1.710 ± 1.730 ± 1.65
SecondaryChange in D-Dimer Levels

D-Dimer levels assessed from blood samples will be evaluated in mcg/ml D-Dimer Units (DDU)

Time frame:
Baseline, Day 9
Reported as:
Mean · mcg/ml DDU
Change in D-Dimer Levels
mcg/ml DDUAT3 Less Than 100% With SOC Plus AT3 SupplementAT3 Less Than 100% With SOC OnlyAT3 More Than 100% With SOC Only
Change in D-Dimer Levels-1.97 ± 5.600.4 ± 3.180.25 ± 2.18
SecondaryChange in Fibrinogen Levels

Fibrinogen levels assessed from blood samples will be evaluated in mg/dL.

Time frame:
Baseline, Day 9
Reported as:
Mean · mg/dL
Change in Fibrinogen Levels
mg/dLAT3 Less Than 100% With SOC Plus AT3 SupplementAT3 Less Than 100% With SOC OnlyAT3 More Than 100% With SOC Only
Change in Fibrinogen Levels-102.1 ± 233.7-123 ± 215.1-111 ± 307.5
SecondaryChange in Prothrombin Time

Prothrombin time assessed from blood samples will be evaluated in seconds.

Time frame:
Baseline, Day 9
Reported as:
Mean · Seconds
Change in Prothrombin Time
SecondsAT3 Less Than 100% With SOC Plus AT3 SupplementAT3 Less Than 100% With SOC OnlyAT3 More Than 100% With SOC Only
Change in Prothrombin Time0.01 ± 2.070.31 ± 1.270.59 ± 1.39
SecondaryLength of Hospital Stay

Length of Hospital Stay reported in days.

Time frame:
Up to 60 days
Reported as:
Median · Days
Length of Hospital Stay
DaysAT3 Less Than 100% With SOC Plus AT3 SupplementAT3 Less Than 100% With SOC OnlyAT3 More Than 100% With SOC Only
Length of Hospital Stay13 ± 15.16 ± 8.358.5 ± 9.46
SecondaryMortality Rate

The number of participants with reported death.

Time frame:
Up to 60 days
Reported as:
Count of participants · Participants
Mortality Rate
ParticipantsAT3 Less Than 100% With SOC Plus AT3 SupplementAT3 Less Than 100% With SOC OnlyAT3 More Than 100% With SOC Only
Mortality Rate233
SecondaryPulmonary Function

Pulmonary Function will be reported as the mean days the participant was on any of the following: mechanical ventilation and/or Extracorporeal Membrane Oxygenation (ECMO) use.

Time frame:
Up to 60 days
Reported as:
Mean · Days
Pulmonary Function
DaysAT3 Less Than 100% With SOC Plus AT3 SupplementAT3 Less Than 100% With SOC OnlyAT3 More Than 100% With SOC Only
Pulmonary Function1.33 ± 5.162.2 ± 6.703.08 ± 6.97
SecondaryChange in SOFA Scores

Sequential Organ Failure Assessment (SOFA) is scored from 0-4 with the higher score indicating more organ failure.

Time frame:
Baseline, Day9
Reported as:
Mean · score on a scale
Change in SOFA Scores
score on a scaleAT3 Less Than 100% With SOC Plus AT3 SupplementAT3 Less Than 100% With SOC OnlyAT3 More Than 100% With SOC Only
Change in SOFA Scores0.43 ± 3.411.23 ± 3.330.64 ± 2.27
SecondaryChange in SOFA Respiratory Sub Score

SOFA Respiratory Sub Score is scored from 0-4 with the higher score indicating worse organ failure.

Time frame:
Baseline, Day 9
Reported as:
Mean · score on a scale
Change in SOFA Respiratory Sub Score
score on a scaleAT3 Less Than 100% With SOC Plus AT3 SupplementAT3 Less Than 100% With SOC OnlyAT3 More Than 100% With SOC Only
Change in SOFA Respiratory Sub Score-0.67 ± 0.98-0.07 ± 0.70-0.17 ± 1.69
SecondaryNumber of Events of Venous Thromboembolism

Number of events of venous thromboembolisms from admission to hospital discharge.

Time frame:
Up to 60 days
Reported as:
Number · Events
Number of Events of Venous Thromboembolism
EventsAT3 Less Than 100% With SOC Plus AT3 SupplementAT3 Less Than 100% With SOC OnlyAT3 More Than 100% With SOC Only
Number of Events of Venous Thromboembolism003
SecondaryNumber of Events of Major Bleeding

Number of events of major bleeding from admission to hospital discharge.

Time frame:
Up to 60 days
Reported as:
Number · events
Number of Events of Major Bleeding
eventsAT3 Less Than 100% With SOC Plus AT3 SupplementAT3 Less Than 100% With SOC OnlyAT3 More Than 100% With SOC Only
Number of Events of Major Bleeding002

Adverse events

Collected over 60 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AT3 Less Than 100% With SOC Plus AT3 Supplement2/15 (13.3%)0/15 (0%)5/15 (33.3%)
AT3 Less Than 100% With SOC Only3/20 (15%)0/20 (0%)5/20 (25%)
AT3 of 100% or More, With SOC Only3/12 (25%)0/12 (0%)8/12 (66.7%)
Most frequent other events
Showing 10 of 36
Most frequent other events
EventAT3 Less Than 100% With SOC Plus AT3 SupplementAT3 Less Than 100% With SOC OnlyAT3 of 100% or More, With SOC Only
Acute Kidney InjuryRenal and urinary disorders2/151/204/12
Worsening Respiratory FailureRespiratory, thoracic and mediastinal disorders1/153/204/12
ShockGeneral disorders1/152/202/12
Atrial FibrillationCardiac disorders0/150/202/12
AnemiaBlood and lymphatic system disorders1/151/202/12
Pulseless Electrical ActivityCardiac disorders1/153/201/12
Heart Failure with reduced Ejection FractionCardiac disorders0/150/201/12
Deep Vein ThrombosisBlood and lymphatic system disorders0/150/201/12
Ureterovesical Junction (UVJ) CalculusRenal and urinary disorders0/150/201/12
Cardiac ArrestCardiac disorders0/150/201/12

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)AT3 Less Than 100% With SOC Plus AT3 SupplementAT3 Less Than 100% With SOC OnlyAT3 More Than 100% With SOC OnlyTotal
<=18 years0000
Between 18 and 65 years1514938
>=65 years56314
Sex: Female, Male
Sex: Female, Male(Participants)AT3 Less Than 100% With SOC Plus AT3 SupplementAT3 Less Than 100% With SOC OnlyAT3 More Than 100% With SOC OnlyTotal
Female67417
Male1413835
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AT3 Less Than 100% With SOC Plus AT3 SupplementAT3 Less Than 100% With SOC OnlyAT3 More Than 100% With SOC OnlyTotal
Hispanic or Latino1014731
Not Hispanic or Latino106521
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AT3 Less Than 100% With SOC Plus AT3 SupplementAT3 Less Than 100% With SOC OnlyAT3 More Than 100% With SOC OnlyTotal
American Indian or Alaska Native0000
Asian0101
Native Hawaiian or Other Pacific Islander0000
Black or African American85417
White1214834
More than one race0000
Unknown or Not Reported0000
08

Study locations

1 site
  • University of Miami
    Miami, Florida 33136, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Mar 2022, 8 months.

Results were first posted in Sep 2022, 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2021
First posted
May 24, 2021
StartActual
Jul 6, 2021
Primary completionActual
Mar 31, 2022
CompletionActual
Mar 31, 2022
Results first posted
Sep 7, 2022
Last update
Sep 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04899232
Lead sponsor
Enrique Ginzburg
Responsible party
Enrique Ginzburg (Professor, University of Miami) — Sponsor-investigator
First posted
May 24, 2021
Start date
Jul 6, 2021
Primary completion
Mar 31, 2022
Completion
Mar 31, 2022
Results posted
Sep 7, 2022
Last update
Sep 7, 2022

Study contacts

Enrique Ginzburg
principal investigator · University of Miami

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Antithrombin III

Start the discussion